Vizimpro FDA Approval History
FDA Approved: Yes (First approved September 27, 2018)
Brand name: Vizimpro
Generic name: dacomitinib
Dosage form: Tablets
Company: Pfizer Inc.
Treatment for: Non-Small Cell Lung Cancer
Vizimpro (dacomitinib) is an oral, once-daily, irreversible pan-human epidermal growth factor receptor tyrosine kinase inhibitor (TKI) indicated for the treatment of metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 19 deletion or exon 21 L858R substitution mutations as detected by an FDA-approved test.
Development timeline for Vizimpro
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.